Mazdutide (Xinermei)
Also known as: Xinermei
Profile at a glance
| Attribute | Value |
|---|---|
| Sponsor | Innovent Biologics (licensed from Eli Lilly) |
| Mechanism | Dual agonist — GLP-1 + glucagon receptors |
| Administration | Once-weekly subcutaneous injection |
| Peak weight loss | ~14–18% (Chinese Phase 3 program) |
| Status | Approved in China (Xinermei) 2025; US Phase 2 ongoing |
Deep dive
What Is Mazdutide (Xinermei)? The First GLP-1/Glucagon Drug Approved in China →The first GLP-1/glucagon dual agonist approved anywhere — how it works, what the trials show, and why it matters for the obesity drug landscape.
Mazdutide (Xinermei) compared
Every head-to-head we've published involving Mazdutide (Xinermei).
Retatrutide vs Mazdutide: Triple vs Dual Agonist Compared
How the triple agonist retatrutide compares to the dual agonist mazdutide on weight loss, diabetes, and liver fat data.
Updated February 2026
Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GLP-1/GIP Compared
Mazdutide pairs GLP-1 with glucagon for liver fat clearance. Tirzepatide pairs GLP-1 with GIP for maximum appetite suppression. Different second receptors, different strengths.
Updated February 2026
Mazdutide vs Survodutide: Two GLP-1/Glucagon Dual Agonists Compared
Both target GLP-1 and glucagon, but mazdutide is approved in China with best-in-class tolerability while survodutide leads on MASH liver data.
Updated March 2026
See all drug profiles in the drug profiles hub or compare drugs head-to-head in the comparisons hub.